In the BioHarmony Drug Report Database

"Preview" Icon

Lemborexant

Dayvigo (lemborexant) is a small molecule pharmaceutical. Lemborexant was first approved as Dayvigo on 2020-04-07. It is used to treat sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against orexin receptor type 2 and orexin receptor type 1. Dayvigo’s patent is valid until 2035-10-21 (FDA).

 

Trade Name

 

Dayvigo
 

Common Name

 

lemborexant
 

ChEMBL ID

 

CHEMBL3545367
 

Indication

 

sleep initiation and maintenance disorders
 

Drug Class

 

Orexin antagonist

Image (chem structure or protein)

Lemborexant structure rendering